Abnova (Taiwan) Corporation Abnova (Taiwan) Corporation

Abnova (Taiwan) Corporation

4133

Rank in Stocks #23947
Abnova (Taiwan) Corporation specializes in the development and distribution of... Abnova (Taiwan) Corporation specializes in the development and distribution of a comprehensive range of recombinant proteins and antibodies. The company's extensive product portfolio caters to diverse research and diagnostic applications, featuring specialized reagents for SARS-CoV/CoV-2, nucleic acids (both DNA and RNA), and various proteins and peptides. Their offerings further include items like DNAxPab, laboratory beads, dyes, cellular lysates, microscopic slides, antibody pairs and associated kits, as well as antibody and tissue arrays. Additionally, they provide in situ hybridization products, advanced laboratory systems and automation, GMP-grade and analyte-specific reagents, and solutions for in vitro diagnostics. Beyond these product lines, Abnova supplies a broad spectrum of antibody types, such as MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and those specifically targeting circulating rare cells. The company also delivers integrated solutions and services, encompassing gene synthesis and cytogenetic analysis, peptide services, protein expression and conjugations, custom antibody generation, and assay development. Abnova (Taiwan) Corporation operates from its headquarters in Taipei, Taiwan.
Share Price
$0.60255961
Last synced: 2026-11-13
Market Cap
$36.49M
Change (1 day)
-0.20%
Change (1 year)
-19.86%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Abnova (Taiwan) Corporation (4133)

Category

Healthcare
Operating Margin for Abnova (Taiwan) Corporation (4133)
Operating Margin as of November 2026 TTM: 7.27%
According to Abnova (Taiwan) Corporation's latest financial reports, its current operating margin (TTM) is 7.27%. At the end of 2025 the company had an operating margin of 4.85%.
Operating Margin history for Abnova (Taiwan) Corporation from 2009 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 7.27% 49.90%
2025 4.85% -49.74%
2024 9.65% -21.86%
2023 12.35% -46.93%
2022 23.27% 178.35%
2021 8.36% -28.24%
2020 11.65% 68.84%
2019 6.90% 35.83%
2018 5.08% -59.10%
2017 12.42% 12.60%
2016 11.03% -2.56%
2015 11.32% -20.62%
2014 14.26% -16.56%
2013 17.09% -13.29%
2012 19.71% -22.55%
2011 25.45% -8.39%
2010 27.78% 20.00%
2009 23.15% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -126.88%
US
33.87% -95.34%
US
-116.04% -115.96%
US
25.57% -96.48%
AU
31.23% -95.70%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Abnova (Taiwan) Corporation's operating margin

What is Abnova (Taiwan) Corporation's operating margin?

Abnova (Taiwan) Corporation's operating margin is 7.27%, as of Nov 2026.

What was Abnova (Taiwan) Corporation's operating margin in 2025?

In 2025, Abnova (Taiwan) Corporation's operating margin was 4.85%, compared with 9.65% in 2024.

How has Abnova (Taiwan) Corporation's operating margin changed since 2020?

From 2020 to 2025, Abnova (Taiwan) Corporation's operating margin was highest in 2022 (23.27%) and lowest in 2025 (4.85%).

How does Abnova (Taiwan) Corporation's operating margin compare with similar companies?

Abnova (Taiwan) Corporation's operating margin (7.27%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.